DocWire News Editors

DocwireNews

Characterizing treatment pathways in a large national commercial payer dataset may provide insight to the way that health care is experienced at the patient level according to a study presented at the 37th ASRS Annual Meeting by Dr. Prithvi Mruthyunjaya, MD, MHS, Associate Professor of Ophthalmology, Director, Ocular Oncology Service, and Director, Vitreoretinal Surgery Fellowship at Stanford Medicine.In this study, researchers identified 27,234 adult patients with a new diagnosis of an eye tumor from the Truven multi-state commercial payer database &ndash; a database containing over seven million records between 2007 and 2015. They applied treatment codes to identify both primary and secondary surgical and clinical procedures. &nbsp;International Classification for Diseases (ICD) codes were used to assess any diagnosis that were consistent with post-treatment retinopathy. The researchers used survival models were to appraise the risk of enucleation and retinopathy based on patients&rsquo; treatment pathways.The study results showed that 3,085 individual patients were identified as having malignant uveal and retinal neoplasms in 2,271 (74%) and 807 (26%) cases, respectively.&nbsp;&nbsp;Moreover, a total of 2,751 patients were administered treatment with the either plaque brachytherapy (PBT) (n=1,521), enucleation (n=604), transpupillary thermotherapy (TTT) (n=380), or proton beam radiation (PrBR) (n=246). Moreover, 486 (32%) patients initially treated with PBT developed post-radiation retinopathy within five years post-treatment, and patients treated with PBT were more likely to develop any form of retinopathy compared to patients treated with PrBR (HR=2.27, 95% CI, 1.54 to 3.34).&ldquo;Characterizing treatment pathways in a large national commercial payer dataset offers insight to the way that health care is experienced at the patient level and is agnostic to the limitations of single center and multi-center studies,&rdquo; the authors wrote in a summation of their study. &ldquo;UM patients will develop post treatment retinopathy and require secondary enucleation at variable rates based on the primary treatment employed.&rdquo;Read more at: <a href="https://meeting2019.asrs.org/ondemand#/ondemand/papers/using-big-data-to-characterize-uveal-tumor-treatment-pathways-and-their-com-638">https://meeting2019.asrs.org/ondemand#/ondemand/papers/using-big-data-to-characterize-uveal-tumor-treatment-pathways-and-their-com-638</a>Mruthyunjaya P. Does Diabetic Status Influence the Rate of Cataract Surgery Following Pars Plana Vitrectomy Surgery? &nbsp;Presented at the 37th ASRS Annual Meeting; July 26-30, 2019; Chicago, IL.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Using Big Data to Characterize Uveal Tumor Treatment Pathways and Their Complications in a Cohort of Commercially Insured Patients

ASRS 2019

Characterizing treatment pathways in a large national commercial payer dataset may provide insight to the way that health care is experienced at the patient level 

Using Big Data to Characterize Uveal Tumor Treatment Pathways and Their Complications in a Cohort of

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe